Regulatory FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries BioSpaceThe FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug's overall risk-benefit profile.RegulatoryImmunology & InflammationRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioSpace The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile. RegulatoryImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: IO Shuts Down Following Regulatory RoadblocksNext: Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
